RxDoctor Payments Data

Gafar Adesoji, MD

Internal Medicine · Southaven, MSNPI 1861414708

Payments from drug & device makers

$2,371in general payments, 2019–2025

Across 158 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$731
  • AstraZeneca$337
  • Novo Nordisk$289
  • Boehringer Ingelheim$197
  • Abbott$128
  • Merck$110
  • plus $578 from 16 others

What the payments were for

  • Food & beverage$2,371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,371 in reported general payments places this provider in the 75th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$144,544
Medicare patients
315
Services billed
2,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide277$297,085
JardianceEmpagliflozin235$199,870
MounjaroTirzepatide76$96,489
EliquisApixaban69$47,327
JanuviaSitagliptin Phosphate35$47,160
LinzessLinaclotide52$35,615
FarxigaDapagliflozin Propanediol24$29,647
JanumetSitagliptin Phos/Metformin Hcl18$29,132
TrulicityDulaglutide22$28,743
Tresiba Flextouch U-100Insulin Degludec12$18,076
XareltoRivaroxaban15$16,101
TopamaxTopiramate14$7,840
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$5,834
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$5,821
Levemir FlexpenInsulin Detemir15$4,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$289$297,085277 claims
Boehringer IngelheimJardiance$197$199,870235 claims
Lilly USA, LLCMounjaro, Trulicity$731$125,23298 claims
MerckJanuvia, Janumet$110$76,29253 claims
PfizerEliquis$52$47,32769 claims
AbbVieLinzess$12$35,61552 claims
AstraZenecaFarxiga, Symbicort$337$33,94440 claims
Johnson & JohnsonXarelto$71$16,10115 claims
Sanofi-aventis U.S. LLCLantus$13$2,84419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Southaven

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →